Scott Paulson1,2, David Ray3, Sharan Aranha4, Amy Scales4, Yunfei Wang4, Eric Liu5. 1. Texas Oncology-Baylor Charles A. Sammons Cancer Center, 3410 Worth St., Suite 400, Dallas, TX, 75246, USA. scott.paulson@usoncology.com. 2. US Oncology Research, Houston, TX, USA. scott.paulson@usoncology.com. 3. Ipsen Biopharmaceuticals, Inc., Cambridge, MA, USA. 4. McKesson Specialty Health, The Woodlands, TX, USA. 5. The Neuroendocrine Institute, Rocky Mountain Cancer Centers, Presbyterian-St. Luke's Hospital, Denver, CO, USA.
Abstract
INTRODUCTION: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) can result in symptoms such as diarrhea, flushing, abdominal pain, and fatigue and are often associated with a significant disease burden and poor prognosis. This non-interventional, prospective, observational study evaluated the real-world safety and effectiveness of lanreotide depot, a somatostatin analog (SSA) used to treat GEP-NETs, in a community setting. METHODS: In this prospective, non-interventional study (NCT02730104), adult patients with locally advanced (inoperable), metastatic GEP-NETs treated with lanreotide depot were evaluated by their physician every 6 months from enrollment for 24 months. Clinically defined time to disease progression (TTDP) and overall survival (OS) were estimated for the total population and by primary tumor type (gastrointestinal [GI], pancreatic, unknown origin), and an exploratory analysis determined the rate of progression-free survival (PFS) at 12 and 24 months. Patient satisfaction was evaluated via the Treatment Satisfaction Questionnaire for Medication (TSQM-9), and safety information was recorded. RESULTS: Of 99 patients, the 24-month PFS rate was 73.7% (95% confidence interval [CI] 63.1-81.7) and 24-month OS rate was 84.2% (95% CI 74.0-90.7). Median TTDP was not reached because few patients experienced disease progression during the study period. The majority of responding patients expressed satisfaction with treatment on each domain of the TSQM-9. Treatment-related adverse events (AEs) occurred in 19.2% of patients, while no serious AEs (SAEs) were related to the study drug. CONCLUSIONS: Lanreotide depot is an effective and well-tolerated treatment for GEP-NETs in the real-world community setting. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02730104.
INTRODUCTION: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) can result in symptoms such as diarrhea, flushing, abdominal pain, and fatigue and are often associated with a significant disease burden and poor prognosis. This non-interventional, prospective, observational study evaluated the real-world safety and effectiveness of lanreotide depot, a somatostatin analog (SSA) used to treat GEP-NETs, in a community setting. METHODS: In this prospective, non-interventional study (NCT02730104), adult patients with locally advanced (inoperable), metastatic GEP-NETs treated with lanreotide depot were evaluated by their physician every 6 months from enrollment for 24 months. Clinically defined time to disease progression (TTDP) and overall survival (OS) were estimated for the total population and by primary tumor type (gastrointestinal [GI], pancreatic, unknown origin), and an exploratory analysis determined the rate of progression-free survival (PFS) at 12 and 24 months. Patient satisfaction was evaluated via the Treatment Satisfaction Questionnaire for Medication (TSQM-9), and safety information was recorded. RESULTS: Of 99 patients, the 24-month PFS rate was 73.7% (95% confidence interval [CI] 63.1-81.7) and 24-month OS rate was 84.2% (95% CI 74.0-90.7). Median TTDP was not reached because few patients experienced disease progression during the study period. The majority of responding patients expressed satisfaction with treatment on each domain of the TSQM-9. Treatment-related adverse events (AEs) occurred in 19.2% of patients, while no serious AEs (SAEs) were related to the study drug. CONCLUSIONS: Lanreotide depot is an effective and well-tolerated treatment for GEP-NETs in the real-world community setting. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02730104.
Authors: Andrea Frilling; Goran Akerström; Massimo Falconi; Marianne Pavel; Jose Ramos; Mark Kidd; Irvin Mark Modlin Journal: Endocr Relat Cancer Date: 2012-09-14 Impact factor: 5.678
Authors: Christophe M Deroose; Elif Hindié; Electron Kebebew; Bernard Goichot; Karel Pacak; David Taïeb; Alessio Imperiale Journal: J Nucl Med Date: 2016-11-03 Impact factor: 10.057
Authors: Jonathan R Strosberg; Al B Benson; Lynn Huynh; Mei Sheng Duh; Jamie Goldman; Vaibhav Sahai; Alfred W Rademaker; Matthew H Kulke Journal: Oncologist Date: 2014-08-05
Authors: Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao Journal: JAMA Oncol Date: 2017-10-01 Impact factor: 31.777
Authors: Edward M Wolin; John Leyden; Grace Goldstein; Teodora Kolarova; Ron Hollander; Richard R P Warner Journal: Pancreas Date: 2017 May/Jun Impact factor: 3.327
Authors: Manisha H Shah; Whitney S Goldner; Al B Benson; Emily Bergsland; Lawrence S Blaszkowsky; Pamela Brock; Jennifer Chan; Satya Das; Paxton V Dickson; Paul Fanta; Thomas Giordano; Thorvardur R Halfdanarson; Daniel Halperin; Jin He; Anthony Heaney; Martin J Heslin; Fouad Kandeel; Arash Kardan; Sajid A Khan; Boris W Kuvshinoff; Christopher Lieu; Kimberly Miller; Venu G Pillarisetty; Diane Reidy; Sarimar Agosto Salgado; Shagufta Shaheen; Heloisa P Soares; Michael C Soulen; Jonathan R Strosberg; Craig R Sussman; Nikolaos A Trikalinos; Nataliya A Uboha; Namrata Vijayvergia; Terence Wong; Beth Lynn; Cindy Hochstetler Journal: J Natl Compr Canc Netw Date: 2021-07-28 Impact factor: 11.908